Park Square is pleased to announce the placement of Eric Lindquist as Chief Business Officer at resistanceBio. resistanceBio is a private, venture-backed biotechnology company that has built the world’s first cancer treatment resistance system to predict how multiple cancer types will respond to approved or novel therapies.

Lindquist is a seasoned business development executive from the pharmaceutical and diagnostic industries who brings a wealth of experience in oncology. He most recently served as Chief Business Officer at Celucity, a publicly traded biopharmaceutical company, where he led all commercial and business development activities, including licensing a phase III ready asset from Pfizer (Gedatolisib). Previously, he served as Global Vice President of Oncology at Natera where he played an integral role in scaling the business. His early career includes roles at Asuragen, Roche, and Abbott.  

Lindquist received his M.B.A. from Capella University as well as a B.S. degree in Genetics and Cell Biology at the University of Minnesota.

Park Square Executive Search serves companies and institutions that are shaping the world through discovery, innovation and growth. Our clients are leading life sciences and healthcare organizations, technology companies, major research universities, and venture capital and private equity firms, including their portfolio companies. We place board members, chief executive officers, C-suite executives, and academic leaders.